MDT

86.26

-0.61%↓

118.39

-1.65%↓

VEEV

167.79

+0.74%↑

HQY

85.02

+3.41%↑

NEOG

9.24

-2.22%↓

MDT

86.26

-0.61%↓

118.39

-1.65%↓

VEEV

167.79

+0.74%↑

HQY

85.02

+3.41%↑

NEOG

9.24

-2.22%↓

MDT

86.26

-0.61%↓

118.39

-1.65%↓

VEEV

167.79

+0.74%↑

HQY

85.02

+3.41%↑

NEOG

9.24

-2.22%↓

MDT

86.26

-0.61%↓

118.39

-1.65%↓

VEEV

167.79

+0.74%↑

HQY

85.02

+3.41%↑

NEOG

9.24

-2.22%↓

MDT

86.26

-0.61%↓

118.39

-1.65%↓

VEEV

167.79

+0.74%↑

HQY

85.02

+3.41%↑

NEOG

9.24

-2.22%↓

Home・Aandelen Lijst・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Open

SectorGezondheidszorg

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	-0.05% downside

Nieuwssentiment

By Acuity

40%

60%

138 / 348 Rangschikking in Healthcare

Mirati Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 apr 2026, 23:14 UTC

Winsten

Battery Maker CATL First-Quarter Net Rose on Strong Demand

15 apr 2026, 23:14 UTC

Winsten

Battery Maker CATL First Quarter Net Rose On Strong Demand

15 apr 2026, 17:13 UTC

Belangrijke Marktbewegers

Tesla Shares Rise on Completion of AI5 Chip Design Process

15 apr 2026, 23:39 UTC

Marktinformatie

Nikkei May Rise After Gains on Wall Street -- Market Talk

15 apr 2026, 23:35 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Rises Amid Hopes for More U.S.-Iran Talks -- Market Talk

15 apr 2026, 22:41 UTC

Winsten

CATL 1Q Net CNY20.74 Vs. Net CNY13.96B >300750.SZ

15 apr 2026, 22:38 UTC

Winsten

CATL 1Q Rev CNY129.13B Vs. CNY84.70B >300750.SZ

15 apr 2026, 22:15 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

15 apr 2026, 22:15 UTC

Marktinformatie

J.B. Hunt Flag Fundamental Shift in 1Q -- Market Talk

15 apr 2026, 22:14 UTC

Winsten

Lens Technology Results Weighed by Lower Rev From Smartphone, Computer Business >300433.SZ

15 apr 2026, 22:12 UTC

Winsten

Lens Technology 1Q Oper Income CNY14.14B Vs. CNY17.06B>300433.SZ

15 apr 2026, 22:11 UTC

Winsten

Lens Technology 1Q Loss CNY149.60M Vs. Net CNY428.88M >300433.SZ

15 apr 2026, 22:11 UTC

Winsten

Lens Technology Swings to Loss in 1Q>300433.SZ

15 apr 2026, 22:07 UTC

Winsten

Big Bank Earnings Show Consumers Are on Solid Ground -- Against All Odds -- Barrons.com

15 apr 2026, 21:34 UTC

Acquisities, Fusies, Overnames

Skild AI Acquires Zebra Technologies' Robotics Automation Business

15 apr 2026, 21:29 UTC

Populaire aandelen

Stocks to Watch: Bank of America, Live Nation, Snap, Hermès -- WSJ

15 apr 2026, 20:50 UTC

Marktinformatie

Winsten

Financial Services Roundup: Market Talk

15 apr 2026, 20:30 UTC

Winsten

PepsiCo Cuts Prices, Revamps Products. Earnings Will Show if It's Working. -- Barrons.com

15 apr 2026, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

15 apr 2026, 20:06 UTC

Marktinformatie

Silver Inches Up as Attention Turns to World Deficit -- Market Talk

15 apr 2026, 19:46 UTC

Winsten

Acquisities, Fusies, Overnames

Jamie Dimon Says JPMorgan Stock Isn't Cheap. Why the Bank Is Still Buying Back Billions. -- Barrons.com

15 apr 2026, 19:25 UTC

Marktinformatie

Automakers' 1Q Earnings Could Give Clues to EV Comeback -- Market Talk

15 apr 2026, 19:00 UTC

Marktinformatie

U.S. Natural Gas Edges Up Ahead of Storage Data -- Market Talk

15 apr 2026, 18:58 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Settles Flat As Market Awaits Conflict Developments -- Market Talk

15 apr 2026, 18:11 UTC

Acquisities, Fusies, Overnames

Three Lessons From Amazon's Blockbuster Deal to Buy Globalstar -- Barrons.com

15 apr 2026, 17:45 UTC

Acquisities, Fusies, Overnames

Apple CEO Tim Cook Buys Nike Stock. His Last Purchase Didn't Go So Well. -- Barrons.com

15 apr 2026, 16:58 UTC

Winsten

Bank of America's Wealth Management Profits Rise Amid 'Resilient' U.S. Economy -- Barrons.com

15 apr 2026, 16:52 UTC

Winsten

Snap and Other Companies Blame AI for Layoffs. Is It Just a Convenient Excuse? -- Barrons.com

15 apr 2026, 16:46 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

U.S. Crude Oil Stocks Finally See Drawdowns -- Market Talk

15 apr 2026, 16:37 UTC

Marktinformatie

Winsten

Global Equities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Mirati Therapeutics Inc Prognose

Koersdoel

By TipRanks

-0.05% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 58.67 USD -0.05%

Hoogste 59 USD

Laagste 58 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Mirati Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Mirati Therapeutics Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

138 / 348 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

EBITDA

Operationele winst

Over Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.